Trial Profile

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148 (SSAIL Trial)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tranexamic acid (Primary)
Indications Septic shock
Focus Therapeutic Use
Acronyms SSAIL
Sponsors Leading BioSciences

Most Recent Events

06 Jun 2016 Status changed from recruiting to discontinued due to inability to enrol participants.
10 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
04 Feb 2015 Planned initiation date changed from 1 Mar 2015 to 1 Jun 2015, as reported in a Leading BioSciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com